Living donor liver transplantation (LDLT) is beneficial, especially in patients with a high risk of wait-list dropout due to tumor burden (beyond Milan) under deceased donor liver transplantation (DDLT) listing criteria but whose objective biology is favorable (low/intermediate AFP, favorable AFP-L3/DCP or MoRAL profile, and low AI-predicted probability of MVI). This evidence concerns the gene AFP and neoplasm.